Determinants of generic drug substitution in Switzerland.
BACKGROUND
Since generic drugs have the same therapeutic effect as the original formulation but at generally lower costs, their use should be more heavily promoted. However, a considerable number of barriers to their wider use have been observed in many countries. The present study examines the influence of patients, physicians and certain characteristics of the generics' market on generic substitution in Switzerland.


METHODS
We used reimbursement claims' data submitted to a large health insurer by insured individuals living in one of Switzerland's three linguistic regions during 2003. All dispensed drugs studied here were substitutable. The outcome (use of a generic or not) was modelled by logistic regression, adjusted for patients' characteristics (gender, age, treatment complexity, substitution groups) and with several variables describing reimbursement incentives (deductible, co-payments) and the generics' market (prices, packaging, co-branded original, number of available generics, etc.).


RESULTS
The overall generics' substitution rate for 173,212 dispensed prescriptions was 31%, though this varied considerably across cantons. Poor health status (older patients, complex treatments) was associated with lower generic use. Higher rates were associated with higher out-of-pocket costs, greater price differences between the original and the generic, and with the number of generics on the market, while reformulation and repackaging were associated with lower rates. The substitution rate was 13% lower among hospital physicians. The adoption of the prescribing practices of the canton with the highest substitution rate would increase substitution in other cantons to as much as 26%.


CONCLUSIONS
Patient health status explained a part of the reluctance to substitute an original formulation by a generic. Economic incentives were efficient, but with a moderate global effect. The huge interregional differences indicated that prescribing behaviours and beliefs are probably the main determinant of generic substitution.
Institute of Health Economics and Management, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Route de Chavannes 31, 1015 Lausanne, Switzerland. anne.decollogny@unil.ch
Anne
A
Decollogny
Yves
Y
Eggli
Patricia
P
Halfon
Thomas M
TM
Lufkin
D011307:Drug Prescriptions; D057915:Drug Substitution / Q000706:statistics & numerical data*; D016568:Drugs, Generic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007344:Insurance Claim Reporting; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012372:ROC Curve; D012051:Reimbursement Mechanisms / Q000191:economics; D013557:Switzerland
D016568:Drugs, Generic
Pharmacoepidemiol Drug Saf. 2004 Apr;13(4):207-14
15255087
Health Policy. 2007 Aug;82(3):366-74
17141355
Curr Med Res Opin. 2007 Jan;23(1):105-16
17257472
Pharm World Sci. 2006 Oct;28(5):284-9
17111247
Pharmacoeconomics. 1997 Jan;11(1):56-63
10165527
Curr Med Res Opin. 2009 Oct;25(10):2515-21
19708764
Health Policy. 2007 May;81(2-3):376-84
16945449
Int J Clin Pharmacol Ther. 2005 Oct;43(10):472-9
16240704
Health Policy. 2000 Apr;51(3):149-62
10720685
Soc Sci Med. 2009 Dec;69(11):1643-50
19815322
JAMA. 2008 Dec 3;300(21):2514-26
19050195
Med Care. 2003 Jun;41(6):761-74
12773842
Health Aff (Millwood). 2009 Mar-Apr;28(2):546-56
19276015
Crit Care Med. 2007 Sep;35(9):2052-6
17568333
Expert Opin Pharmacother. 2009 Oct;10(14):2317-28
19663636
Int J Pharm Pract. 2009 Apr;17(2):79-88
20214255
Epilepsy Behav. 2007 Aug;11(1):46-52
17537678
Arch Intern Med. 2006 Feb 13;166(3):332-7
16476874
PLoS Med. 2007 Sep;4(9):e283
17896856
Pharmacoepidemiol Drug Saf. 2005 May;14(5):341-8
15624198